The Manufacturers Life Insurance Company Takes $4.54 Million Position in Bruker Corporation $BRKR

The Manufacturers Life Insurance Company acquired a new stake in shares of Bruker Corporation (NASDAQ:BRKR) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 75,380 shares of the medical research company’s stock, valued at approximately $4,536,000.

Other large investors also recently bought and sold shares of the company. Pallas Capital Advisors LLC bought a new position in Bruker in the second quarter valued at about $570,746,000. Orbis Allan Gray Ltd bought a new stake in shares of Bruker during the 2nd quarter valued at about $192,735,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Bruker during the 2nd quarter valued at about $169,899,000. Price T Rowe Associates Inc. MD increased its position in shares of Bruker by 2,963.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after purchasing an additional 2,289,269 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Trading Up 1.6%

Shares of NASDAQ:BRKR opened at $58.01 on Tuesday. The stock has a 50 day moving average of $58.80 and a 200 day moving average of $48.16. The company has a market cap of $8.84 billion, a PE ratio of -82.87, a price-to-earnings-growth ratio of 1.75 and a beta of 1.28. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $65.30.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same period in the prior year, the firm posted $0.32 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s dividend payout ratio is -28.57%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of a number of research reports. Citigroup dropped their price objective on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a report on Wednesday, August 5th. Guggenheim increased their price target on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Finally, Leerink Partners upped their price objective on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.64.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.